Clearside Biomedical (CLSD, Financial) has been downgraded from a "Buy" to a "Neutral" rating by HC Wainwright & Co. Analyst Yi Chen is responsible for the latest reevaluation.
The analyst has maintained the price target for Clearside Biomedical (CLSD, Financial) at USD 5.00, unchanged from the previous target. Despite the change in rating, the price target remains consistent with prior assessments.
This update on Clearside Biomedical (CLSD, Financial) comes as part of an ongoing evaluation by analysts to reflect current market conditions and company performance.
The rating and price target change are effective as of July 18, 2025, and are aimed at providing investors with up-to-date insights into the company's market positioning.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Clearside Biomedical Inc (CLSD, Financial) is $5.50 with a high estimate of $8.00 and a low estimate of $3.00. The average target implies an upside of 813.92% from the current price of $0.60. More detailed estimate data can be found on the Clearside Biomedical Inc (CLSD) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Clearside Biomedical Inc's (CLSD, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Clearside Biomedical Inc (CLSD, Financial) in one year is $0.37, suggesting a downside of 38.52% from the current price of $0.6018. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Clearside Biomedical Inc (CLSD) Summary page.
